Mometasone Furoate Cream USP, 0.1%, packaged in a) 15gram tubes (NDC 68462-192-17) and b) 45 gram...
FDA Drug Recall #D-1586-2019 — Class II — July 23, 2019
Recall Summary
| Recall Number | D-1586-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 23, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Glenmark Pharmaceuticals Inc., USA |
| Location | Mahwah, NJ |
| Product Type | Drugs |
| Quantity | N/A |
Product Description
Mometasone Furoate Cream USP, 0.1%, packaged in a) 15gram tubes (NDC 68462-192-17) and b) 45 gram tubes (NDC 68462-192-55), Rx Only, Manufactured by; Glenmark Pharmaceuticals Ltd At: Village: Kishanpura, Baddi Nalagari Road, District: Solan, Himachal Pradesh -173205, India Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430
Reason for Recall
GMP Deviations: Glenmark received complaints stating that mometasone fuorate cream was gritty.
Distribution Pattern
Nationwide within the United States
Lot / Code Information
a) 05171238, 05171248, 05171249, Exp. Jul-2019; 05171582, 05171612, Exp. Aug-2019; 05171674, 05171675, 05171682, Exp. Sep 2019; 05180065, 05180066, Exp. Dec 2019; 05180264, 05180264, 05180265, 05180275, 0518276, Exp. Jan 2020; 05180411, 05180412, 05180422, Exp. Jan 2020; 05180556, 05180568 Exp..Feb-2020; 05180889, 05180890, 05180896, 05180896, 05180897 Exp. Apr 2020; 05181123, 05181129, 05181134, 05181135, Exp. May 2020; 05181415, 05181425, 05181429, 05181433, Exp. Jun 2020; 05181528, Exp. Jul 2020; 05181747, 05181748, Exp. Aug 2020. b) 05171207, 05171212, 05171213, 05171232, 05171233, Exp. Jul-2019; 05171476, 05171478, 05171479, Exp. Aug 2019; 05171596 , 05171597, 05171602, 05171603, Exp. Aug 2019; 05171683, 05171697, 05171698, 05171703, 05171718, 05171783, 05171788, 05171789, 05171790, 05171791, Exp. Sep 2019; 05180092, 05180093, 05180119, 05180219, 05180220, Exp. Dec 2019; 05180289, 05180291, 05180434,05180435, Exp. Jan-2020; 05180438, 05180439, 05180443, 05180444, 05180450, 05180462, 05180572, 05180646, Exp. Feb 2020 05180648, 05180649, 05180659, 05180660, 05180671, Mar 2020; 05180870, 05180871, 05180874, 05180877, 05180900, 05180901, Exp. Apr 2020; 05181073, 05181074, 05181086, 05181087, 05181091, 05181092, 05181101, 05181102, 05181111, 05181146, 05181147, 05181148, 05181240 Exp. May 2020; 05181241, 05181248, 05181252, 05181253, 05181257, 05181265, 05181266, 05181267, 05181272, 05181309, 05181316, 05181317, 05181332 Exp. Jun 2020; 05181588, 05181602, 05181603, 05181618, 05181619, 05181621, 05181622, 05181633, 05181634 Exp. Jul 2020; 05181754, 05181772, 05181773, 05181781 Exp. Aug 2020
Other Recalls from Glenmark Pharmaceuticals Inc., USA
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0246-2026 | Class II | Ondansetron Orally Disintegrating Tablets, USP,... | Dec 30, 2025 |
| D-0199-2026 | Class III | Bisoprolol Fumarate and Hydrochlorothiazide Tab... | Nov 21, 2025 |
| D-0222-2026 | Class III | Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, ... | Nov 18, 2025 |
| D-0662-2025 | Class II | Azelaic Acid Gel, 15%, 50 grams, For Topical Us... | Sep 17, 2025 |
| D-0021-2026 | Class II | Viorele, Desogestrel and Ethinyl Estradiol, USP... | Sep 3, 2025 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.